Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Akebia Therapeutics, Inc.
Bear Case (25th pct.)
-7.1% vs price
Base Case (Median)
-3.6% vs price
Bull Case (75th pct.)
23.1% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $0.83 | -3.5% | High (40%) |
| EV/EBITDA | $1.30 | 50.9% | Medium (20%) |
| Earnings Power Value | $0.77 | -10.8% | Medium (50%) |
Based on 3 out of 7 methods, AKBA appears fairly valued at the current price of $0.86. The base case fair value of $0.83 implies 3.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.